Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Development of ALK-directed TCR-T cells with potent and specific anti-tumor activity against ALK-positive anaplastic large cell lymphoma

Simone Piane, Carmen Mecca, Nirmala Tilijia Pun et al. Nov 03, 2025 pp. 5909-5909 10.1182/blood-2025-5909

Abstract Introduction: Anaplastic Lymphoma Kinase (ALK)-positive Anaplastic Large Cell Lymphoma (ALCL) is a subtype of T-cell lymphoma repre...

Integrated clinical and radiomic PET-FLIPI score for risk stratification in newly diagnosed follicular lymphoma

Rexhep Durmo, Stephane Chauvie, Carla Minoia et al. Nov 03, 2025 pp. 3561-3561 10.1182/blood-2025-3561

Abstract Background: Follicular lymphoma (FL) has a heterogeneous clinical course, and despite advances in therapy, a significant proportion...

Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium

Onyee Chan, Michael Walker, Deedra Nicolet et al. Nov 03, 2025 pp. 1626-1626 10.1182/blood-2025-1626

Abstract Background: The discovery of IDH1/2 mutations in AML has resulted in FDA approving therapies targeting IDH1/2. Similarly, the chang...

Nemtabrutinib plus venetoclax in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the dose escalation and confirmation segment of the Phase 3 bellwave-010 study

Paolo Ghia, Mauricio Chandia Cabas, Vernon Johan Louw et al. Nov 03, 2025 pp. 2119-2119 10.1182/blood-2025-2119

Abstract Introduction: Venetoclax + rituximab (VR) is a standard-of-care therapy for patients with relapsed or refractory (R/R) chronic lymp...

Self-reported prophylaxis treatment experience among persons living with hemophilia A in the US: A cross-sectional analysis of survey results combined with medical records

Molly Scannell Bryan, Eleni Demas, Carmine Colavecchia et al. Nov 03, 2025 pp. 4842-4842 10.1182/blood-2025-4842

Abstract Background: In hemophilia A (HA), prophylaxis is used to prevent bleeding and joint damage. With the expansion of non-factor therap...

Representativeness of clone size measurement by using NGS-based immunoglobulin gene rearrangement test in comparison to flow cytometry in clonal plasma cell disorders

Hyeseong Ryu, Daehyun Chu, Jiyeon Kim et al. Nov 03, 2025 pp. 5787-5787 10.1182/blood-2025-5787

Abstract Introduction: Next-generation sequencing (NGS) IG gene rearrangement test provides quantitative information about the clone, which...

Enhancing the expansion of Naïve, potent T-cells via BTK inhibition reinvigorates CD19-CAR T-cell immunity and boosts antitumor efficacy in relapsed Mantle Cell Lymphoma

Yixin Yao, Yue Fei, Xiaolin Li et al. Nov 03, 2025 pp. 1785-1785 10.1182/blood-2025-1785

Abstract Background Emerging evidence indicates that inhibition of BTK and tyrosine kinases enhances immune responses and potentiates CAR T-...

Impact of inhibitors positivity on treatment patterns and disease burden in Chinese patients with hemophilia: A cross-sectional real-world study

Xuefei Bai, Lei Gan, Xiaoning He et al. Nov 03, 2025 pp. 6617-6617 10.1182/blood-2025-6617

Abstract Hemophilia is an X-linked inherited bleeding disorder characterized by a deficiency of coagulation factor VIII or IX, leading to re...

Immunogenicity assessment of concizumab in patients with Hemophilia A and b: Assays developed to measure anti-drug antibodies and integrated results from clinical trials

Luis Perez Tosar, Thomas Porstmann, Lone Hummelshøj Landsy Nov 03, 2025 pp. 4848-4848 10.1182/blood-2025-4848

Abstract Background Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody indicated for patients with hemophilia...

Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party

Nour Moukalled, Jacques-Emmanuel Galimard, Ali Bazarbachi et al. Nov 03, 2025 pp. 6079-6079 10.1182/blood-2025-6079

Abstract Introduction Allogeneic hematopoietic stem cell transplantation (HSCT) remains a mainstay in the treatment of acute myeloid leukemi...

Inotuzumab ozogamicin vs blinatumomab bridging optimization and second CD19 CAR-T efficacy in Relapsed/Refractory B-ALL

Lin Liu, Danying Liao, Weijiayi Wang et al. Nov 03, 2025 pp. 2398-2398 10.1182/blood-2025-2398

Abstract Introduction: Despite advances with CD19 chimeric antigen receptor T-cells (CAR-T) in relapsed/refractory B-cel...

Clinical impact of delays in insurance authorization for newly diagnosed Acute Myeloid Leukemia considered for intensive induction chemotherapy

Daniel Olivieri, Fazal Yakub, Gurbani Kaur et al. Nov 03, 2025 pp. 4426-4426 10.1182/blood-2025-4426

Abstract Introduction: Expert guidelines recommend investigational therapy as first-line treatment for many patients with acute myeloid leuk...

Study on five-year continuous improvement path for perianal infection prevention and control in hematopoietic stem cell transplantation Patients—Achieving zero infection through data-driven and optimized nursing schemes

Xiaoxia Wang Nov 03, 2025 pp. 5989-5989 10.1182/blood-2025-5989

Abstract Perianal infection is common in HSCT patients. Due to mucosal barrier damage and severe immunosuppression from conditioning regimen...

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Saurabh Zanwar, Oren Pasvolsky, Doris Hansen et al. Nov 03, 2025 pp. 4069-4069 10.1182/blood-2025-4069

Abstract Introduction: Bispecific T-cell engagers (TCE) targeting BCMA (teclistamab, elranatamab) and GPRC5D (talquetamab) are important ther...

Epidemiology and outcomes of patients with myeloproliferative neoplasms in the United States: A SEER database analysis, years 2000-2021

Sachi Singhal, Rahul Mishra, Sankalp Arora et al. Nov 03, 2025 pp. 2048-2048 10.1182/blood-2025-2048

Abstract Background: Classic MPNs include Essential Thrombocythemia (ET), Polycythemia Vera (PV), Primary Myelofibrosis (PMF), and Chronic M...

A multi-timepoint immune profiling model for differentiating gvhd- and infection-associated diarrhea following allo-HSCT

Man Chen, Wei Zhao, Hui Wang Nov 03, 2025 pp. 4231-4231 10.1182/blood-2025-4231

Abstract Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for various hematologic malignanc...

Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the chariot trial

Sairah Ahmed, Jinwen Cao, Matthew Mei et al. Nov 03, 2025 pp. 1844-1844 10.1182/blood-2025-1844

Abstract Introduction Autologous CD30-directed chimeric antigen receptor T-cell (CD30.CAR-T) therapy has demonstrated fa...

Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease.

John Koreth, Maria Carmen Martinez Munoz, Jeremy Pantin et al. Nov 03, 2025 pp. 274-274 10.1182/blood-2025-274

Abstract Introduction: Itolizumab is a non-depleting, monoclonal antibody against CD6 that blocks its interaction with activated leukocyte c...

Functional difference of CAR T-cells prepared from peripheral stem cell collections and peripheral lymphocyte collections

Xi Ming, Rubing Zheng, Jiaying Wu et al. Nov 03, 2025 pp. 7705-7705 10.1182/blood-2025-7705

Abstract Introduction: CAR T-cell immunotherapy involves the collection of T cells, followed by ex vivo genetic modification, expansion, and...

Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma

Xiaomeng Sun, Charlotte Graham, Aiyana Parker et al. Nov 03, 2025 pp. 503-503 10.1182/blood-2025-503

Abstract Introduction Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapies, including FDA-approved ciltaca...

A practical tool for predicting outcomes in essential thrombocythemia: Triple (or quadruple) a risk model

Ozge Sonmez, Esiyla Oyur, Ipek Yonal Hindilerden et al. Nov 03, 2025 pp. 3805-3805 10.1182/blood-2025-3805

Abstract Introduction: Essential thrombocythemia (ET) is generally an indolent disease, but it can be complicated by thrombosis, bleeding, pr...

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change

Suzanne Trudel, Vania Hungria, María-Victoria Mateos et al. Nov 03, 2025 pp. 5823-5823 10.1182/blood-2025-5823

Abstract Background: In DREAMM-7 (NCT04246047), belantamab mafodotin (belamaf) in combination with bortezomib and dexamethasone (BVd) demons...

Implementation of a multidisciplinary quality improvement project standardizing an approach to screening and treating iron deficiency in pregnancy

Richard Godby, Myra Wick, Mingchun Liu et al. Nov 03, 2025 pp. 595-595 10.1182/blood-2025-595

Abstract Introduction: Iron deficiency (ID) is a global epidemic with discrepant definitions of both ID and anemia in pregnancy. Iron requir...

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Jing-Zhou Hou, Tae Min Kim, Seok-Goo Cho et al. Nov 03, 2025 pp. 1005-1005 10.1182/blood-2025-1005

Abstract Introduction: Surovatamig (formerly AZD0486) is a novel, IgG4 fully human CD19xCD3 bispecific T-cell engager (TCE) being evaluated...

Establishment and validation of an optimized prognostic model for Chinese patients with chronic myelomonocytic leukemia (Sino-CPSS): A 231-patient single-center study

Qingli Ji, Xinwen Jiang, Dongmei Hu et al. Nov 03, 2025 pp. 7378-7378 10.1182/blood-2025-7378

Abstract Background: Chronic myelomonocytic leukemia (CMML) exhibits significant survival heterogeneity. Existing prognostic models based on...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page